Santaris Pharma has appointed Arthur Levin, its chief development officer, as president of its new California-based subsidiary.
Levin previously served as vice president of drug development at Isis Pharmaceuticals. He holds a PhD in toxicology from the University of Rochester School of Medicine and Dentistry.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
